Prostate Cancer is the most common non-skin cancer in America. More than 234,000 men will be diagnosed with prostate cancer this year. If you have been diagnosed with Prostate Cancer, you may be eligible to participate in a new clinical trial being conducted by Novartis Oncology.

This study is designed to evaluate the safety and effectiveness of a new investigational drug called Patupilone, compared to an existing drug called docetaxel. If you or a friend or family member has a diagnosis of prostate cancer and have not yet received treatment for your cancer, you may be eligible to participate in this study.

to learn more about this study.